| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012464692 |
| P356 | DOI | 10.1007/S00417-013-2552-8 |
| P698 | PubMed publication ID | 24366669 |
| P2093 | author name string | Ethan Priel | |
| Radgonde Amer | |||
| Michal Kramer | |||
| Ronit Friling | |||
| Michal Schaap-Fogler | |||
| P2860 | cites work | Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. | Q33920749 |
| Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. | Q34239414 | ||
| Medical treatment of cystoid macular edema | Q35174908 | ||
| Cytokines and uveitis, a review | Q35723218 | ||
| Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations | Q35763093 | ||
| Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(-) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study | Q35820405 | ||
| Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis | Q35904466 | ||
| The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. | Q36441711 | ||
| Inflammatory mediators of uveitis: cytokines and chemokines. | Q36634978 | ||
| Causes and frequency of blindness in patients with intraocular inflammatory disease | Q37319691 | ||
| Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease | Q37582657 | ||
| Vascular endothelial growth factor inhibition in uveitis: a systematic review | Q37759966 | ||
| Clinical Review: Update on Treatment of Inflammatory Macular Edema | Q37804876 | ||
| Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. | Q42869100 | ||
| Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes | Q42970412 | ||
| Cytokines in uveitis | Q43023989 | ||
| Intravitreal adalimumab for refractory uveitis-related macular edema. | Q43105859 | ||
| Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema | Q44676246 | ||
| Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis | Q44798829 | ||
| Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema | Q44835234 | ||
| Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema | Q46062208 | ||
| Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis | Q46074801 | ||
| Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete. | Q46606401 | ||
| Somatostatin for Uveitic Cystoid Macular Edema (CME). | Q46830843 | ||
| Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis | Q47343514 | ||
| Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. | Q47987954 | ||
| Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. | Q48637345 | ||
| Risk factors for the development of macular edema in noninfectious uveitis. | Q51060569 | ||
| Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. | Q51330423 | ||
| Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. | Q51738074 | ||
| Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions | Q57767982 | ||
| Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical Uveitis | Q61895192 | ||
| Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema | Q79826333 | ||
| Impact of macular edema on visual acuity in uveitis | Q80023608 | ||
| Infliximab for chronic cystoid macular edema associated with uveitis | Q80871601 | ||
| Proteomic analysis of vitreous from diabetic macular edema | Q81006910 | ||
| Adalimumab therapy for refractory uveitis: a pilot study | Q81267829 | ||
| Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis | Q83160921 | ||
| Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema | Q85057723 | ||
| P433 | issue | 4 | |
| P921 | main subject | uveitis | Q280027 |
| cystoid macular edema | Q18556331 | ||
| P304 | page(s) | 633-640 | |
| P577 | publication date | 2013-12-24 | |
| P1433 | published in | Graefe's Archive for Clinical and Experimental Ophthalmology | Q15757667 |
| P1476 | title | Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis | |
| P478 | volume | 252 |
| Q41458186 | Adalimumab Reduces Photoreceptor Cell Death in A Mouse Model of Retinal Degeneration. |
| Q90614897 | Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis |
| Q94333937 | Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis |
| Q49845401 | DOG and BVA guideline no. 24b : Noninfectious uveitis posterior |
| Q39181648 | Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study |
| Q92859254 | Emerging therapies in the management of macular edema: a review |
| Q92157963 | Insights into the pathogenesis of cystoid macular edema: leukostasis and related cytokines |
| Q90397147 | Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges |
| Q92244355 | New onset or exacerbation of uveitis with infliximab: paradoxical effects? |
| Q35848384 | Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema |
| Q90704178 | The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study |
| Q63581754 | Treatment and functional outcome of patients with cystoid macular edema: a single-center experience |
| Q64226421 | Update in treatment of uveitic macular edema |
Search more.